Liquid Biopsy Holds Its Own in NSCLC.
According to the prospective NILE study, cell-free DNA analyses are at least as good as tissue-based genotyping for identifying therapeutically actionable genomic alterations in patients with non-small cell lung cancer; the turnaround time is also significantly shorter.